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I. / 
(a) Penemuan Projek! Abstrak 
(Perlu disediakan makluman di antara 100- 200 perkataan di dt;zlam Bahasa 
Malaysia dan Bahasa lnggeris. lni kemudiannya akan dimuatkan ke dalam 
Laporan Tahunan Bahagian Penyelidikan & Pembangunan sebagai satu cara 
untuk menyampaikan dapatan projek tuanlpuan kepada pihak Universiti). 
Berbagai disfungsi organ endokrin diketahui berlaku pada kanak-kanak talasemia. yang memerlukan 
transfusi darah. Keabnormalan ini mungkin disebabkan oleh pengarnbilan melarnpau zat besi atau 
hipoksia yang disebabkan oleh anemia kronik. Kajian-kajian rembesan hormon tumbesaran selepas 
rangsangan telah memberi keputusan yang berbeza-beza. Kebanyakan kajian ini dilakukan ke atas kanak-
kanak yang menghidapi penyakit talasernia major dan tidak banyak kajian dilakukan ke atas kanak-kanak 
yang menghidap penyakit ~-thalassernia/Hb E yang lebih biasa didapati di rantau ini. 
Tujuan: Tujuan kajian ini adalah untuk membandingkan corak rembesan hormon tumbesaran dan IGF-1 
serum di antara kanak-kanak yang menghidapi penyakit talasemia dan kanak-kanak normal. 
,. 
Kaedah: Pesakit talasernia berumur 6-12 tahun yang memerlukan transfusi darah secara regular di 
Hospital USM dari Oktober 1993 hingga Oktober 1995 dipilih secara rawak untuk kajian ini. Semua 
pesakit ini tidak ada riwayat keluarga malnutrisi, diabetes mellitus, kekerdilan atau penyakit endokrin 
lain . Kanak-kanak normal yang sihat dipilih daripada anak kakitangan USM. 
Ketinggian, umu- tulang, feritin serum dan IGF-1 serum disukat pada semua kanak-kanak. Hormon 
rumbesaran serum disukat selepas dirangsang dengan senaman dan glukagon intravena. Kedua-dua 
hormon tumbesaran serum dan IGF-1 serum disukat secara radioimunoasai. 
Keputusan: Sejurnlah 22 pesakit tal asemia ( 4 ~-tal asemia major and 18 HbFJ~-talasemia) dan 10 
kanak-kanak normal telah dikaji . Tidak ada perbezaan jantina, min umur kronologikal dan min umur 
rulang di antara pesakit talasernia dan kanak-kanak normal. "Z-scores" and feritin serum didapati lebih 
tinggi pada pesakit talasemia jika dibandingkan dengan kanak-kanak normal. Aras tiroksin serum dan 
hormon perangsang tiroid ditfabti normal dalarn kedua-dua kumpulan. 
Min aras puncak hormon tumbesaran serum selepas senaman dan glukagon intravena ialah 4.2 ug/L and 
3.8 ug/L dalarn pesakit talasernia dan 3.6 ug/L and 4.8 ug/L dalarn kanak-kanak normal . Perbezaan 
hormon tumbesaran serum di antara kedua-dua kumpulan ini tidak signifikan. Tetapi aras min IGF-1 
serum adalah lebih tinggi (p = 0.001) pada kanak-kanak normal (25 .5 ng/L) jika dibandingkan dengan 
pesakit talase~a (12.3 ng/L). Dalam pesakit talasemia tidak ada korelasi di antara feritin serum dan 
umur kronologi (r = - 0.04). Tetapi terdapat korelasi rendah di antara aras feritin serum dan min aras 
puncak horrnon tumbesaran serum selepas senaman(r =- 0.30) dan rangsangan glukagon (r = - 0.29). 
Kesimpulan: Kajian ini menunjukkan bahawa pada kanak-kanak talasernia, rembesan horrnon 
rumbesaran (seperti yang dinilai dengan gerakbelas terhadap rangsangan senaman dan glukagon) tidak 
teijejas sementara penjanaan IGF-1 serum pula berkurangan. Gangguan horrnon tumbesaran mungkin 
berlaku lebih lewat jika dibandingkan dengan gangguan IGF-1 serum. Kekurangan IGF-1 serum ini 
merupakan satu daripada beberapa faktor yang menyebabkan kekerdilan pada penghidap talasemia, dan 
mungkin disebabkan oleh pemendapan zat besi dalam hati. Keabnorrnalan endokrin ini dapat dielakkan 
sekiranya aras hemoglobin dapat dikawal dan terapi pengkelatan besi digunakan oleh semua pesakit 
talasernia. 
4) (a) Penemuan Projek/Abstrak 
(Perlu disediakan makluman di antara 100-200 perkataan di dalamBahasa 
Malaysia dan Bahasa lnggeris. Ini kemudiannya akan dimuatkan ke dalam 
Laporan Tahunan Bahagian Penyelidikan & Pemba.,;gunan sebagai satu· cara 
untuk menyampaikan dapatan projek tuanlpuan kepada pihak _Universiti). 
Various endoc.rine organ dysfunctions are known to be affected .in children with transfusion dependent 
thalassemia. These abnonD.alities may be due to iron overload or. chronic hypoxia as a result of chronic 
anaemia. Studies of growth hormone secretion following provocation tests have shown conflicting 
results. While most of these studies were done in children with P-thalassemia major, few studies were 
done in patients with P-thalassemia/Hb E disease which is more prevalent in this region. 
Aim: The aim of this study is to compare the pattern of growth hormone secretion and serum IGF-1 in 
children with transfusiop dependent thalassemia and normal children. 
Method: Children aged 6-12 years with transfusion dependent thalassemia were randomly selected from 
children with thalassemia admitted to University of Science Malaysia Hospital from October 1993 to 
October 1995. None of the patients gave a family history of malnutrition, diabetes mellitus, dwarfism or 
other endocrine diseases. Normal children volunteers were mainly healthy children of staff members in 
the hospital. 
The heights, bone age, serum ferritin and serum IGF-1 were measured in all the children. Serum growth 
hormone was measured following stimulation with exercise and intravenous glucagon. Both serum 
growth hormone and serum IGF-1 were estimated by radioimmunoassay using a double antibody. 
Results: A total of 22 thalassemic children (4 P-thalassemia major and 18 HbEIP-thalassemia) and 10 
normal children were studied. There was no difference in sex, mean chronological age and mean bone 
age between thalassemic and..flprmal children. The Z-scores and serum ferritin were significantly more in 
thalassemic than normal children. The serum thyroxine and thyroid stimulating hormone were normal in 
both groups. 
The mean peak serum growth hormone following exercise and intravenous glucagon was 4.2 ug/L and 
3.8 ug!L in thalassemic children and 3.6 ug/L and 4.8 ug/L in normal children respectively. There were 
not statistically significant. The mean serum IGF-1 levels was significantly higher (p = 0.001) in the 
normal (25.5 ng/L) than the thalassemia children (12.3 ng/L). In thalassemia children there was no 
correlation between serum ferritin and .age (r =- 0.04) and between serum ferritin level and serum IGF-1 
levels (r = 0.01). There was only a weak negative correlation between serum ferritin and peak growth 
hormone levels after exercise (r = - 0.30) and glucagon stimulation (r = - 0.29). 
Conclusion: GH secretion, as evaluated by the responses to exercise and glucagon stimulation, is not 
impaired, while the generation of serum IGF-1 is reduced in this group of thalassemic children. 
Comparison of these data with those of other published reports indicate that impairment of GH secretion 
may occur later in the course of the disease. A reduction in IGF-1 production probably secondary to 
excessive iron deposition in the liver is manifested earlier. The presence of impaired IGF-1 production 
may be a cause of short stature in these children. The achievement of relatively constant haemoglobin 
levels and reduction of tissue iron stores with long term iron chelation therapy is needed to prevent these 
endocrine abnormalities. 
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(b) Senaraikan Kata-Kunci yang digunakan di dalam abstrak: 
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6. Peral~tan Yang Telah Dibeli: 
a. Glucagon 
b. Growth hormone double antibody radioimmunoassay kit 
c. IGF-1 double antibody radioimmunoassay kit 
d. Ferritin assay kit 
e. Blood sugar assay 
•' f. X-ray films 
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Various endocrine organ dysfunctions are known to be affected in children with transfusion 
dependent thalassemia. These abnormalities may be due to iron overload or chronic hypoxia as a 
result of chronic anaemia. Studies of growth hormone secretion following provocation tests have 
shown conflicting results. Most published studies were done in children with ~-thalassemia 
major and there are few studies done in patients with ~-thalassemia/Hb E disease which is more 
,. 
prevalent in this region. 
Aim: The aim of this study is to compare the pattern of growth hormone secretion following 
provocation tests and serum IGF-1 in children with transfusion dependent thalassemia and 
normal children. 
Method: Children aged---~12 years with transfusion dependent thalassemia were randomly 
selected from children with thalassemia admitted to University of Science Malaysia Hospital 
from October 1993 to October 1995. None of the patients gave a family history of malnutrition, 
diabetes mellitus, dwarfism or other endocrine diseases. Normal children volunteers were mainly 
healthy children of staff members in the hospital and patients who were well. 
The heights, bone age, serum ferritin and serum IGF-1 were measured in all the children. Serum 
growth hormone was measured following stimulation with exercise and intravenous glucagon. 
Both serum growth hormon~ and serum IGF-1 were estimated by radioimmunoassay using a 
double antibody. 
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Fesults: A total of 22 thalassemic children ( 4 P-thalassemia major and 18 HbE/P-thalassemia) 
and 10 normal children were studied. There were no difference in sex, mean chro~ological age 
and mean bone age between thalassemic and normal children. The Z-scores and serum ferritin 
f were significantly more in thalassemic than normal children. The serum thyroxin and thyroid 
i 
{ stimulating hormone were normal in both groups. 
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t 
The mean peak serum growth hormone following exercise and intravenous glucagon was 4.2 
ug/L ru:.rd 3.8 ug/L in thalassemic children and 3.6 ug/L and 4.8 ug!L in normal children 
respectively. There were not statistically significant. The mean serum IGF-1 levels were 
significantly higher (p = 0.001) in normal (25.5 ng!L) than in thalassemia children (12.3 ng!L). 
In thalassemia children there was no correlation between serum ferritin and chronological age (r 
=- 0.04) and between serum ferritin and serum IGF-1 levels (r = 0.01). There was only a weak 
negative correlation between serum ferritin and peak growth hormone levels after exercise (r = 
- 0.30) and glucagon stimulation (r = - 0.29) . 
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Conclusion: GH secretion, as evaluated by the responses to exercise and glucagon stimulation, 
is not impaired, while the generati0n of serum IGF-1 is reduced in this group of thalassemic 
children. Comparisons of these data with those of other published reports indicate that 
impairment of GH secretion may occur later in the course of the disease. A reduction in IGF-1 
-production probably secondary to excessive iron deposition in the liver is manifested earlier. 
The presence of impaired IGF-1 production may be a cause of short stature in these children. The 
achievement of relatively constant haemoglobin levels and reduction of tissue iron stores with 
·long term iron chelation therapy is needed to prevent these endocrine abnormalities. 
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Children with P-thalassemia, a severe hereditary disorder of haemoglobin synthesis, frequently 
require regular blood transfusion. Many of these children also have short stature that may be 
secondary to endocrine dysfunction [1,2,3] 
Various endocrine organs have been reported to be affected in children with transfusion 
dep~ndent thalassemia and this is thought to be due to the consequence of iron overload [4,5,6] . 
It is known that subjects with the disease accumulate large quantities of iron (as ferritin) in many 
organs secondary to blood transfusion and increased intestinal iron absorption [7). Besides iron 
overload, chronic hypoxia secondary to chronic anaemia has also been postulated to cause 
abnormalities in endocrine function. Iron deposition in the pituitary or hypothalarnus[8] may be 
responsible for impaired secretion of growth hormone reported in many patients with transfusion 
dependent thalassemia major. 
~ .. 
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Endocrine studies in these children have frequently but not always revealed the presence of 
normal growth hormone response to provocative stimuli [5,6,9,10]. Several studies investigating 
the pattern of growth hormone have been published. While many studies have .shown that the 
secretions of growth hormone to provocative tests were normal, many other studies have 
demonstrated suppressed secretion of growth hormone following provocative tests. The presence 
of short stature and normal pattern of growth secretion in thalassemic children have lead others 
to investigate the levels of somatomedins and neurosecretary function in these children. A 
marked reduction of somatomedin activity [11 ,12] and abnormal neurosecretary functions [10] 
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nave both been demonstrated and it is thought to be the underlying cause of short stature in these 
children . 
Most reported studies were done in children with ~-thalassemia major and there were few 
studies done in patients with ~-thalassernia!Hb E disease which is more prevalent in this region. 
This study aims to study the pattern of growth hormone (GH) secretion and serum IGF-1 m 
children with transfusion dependent thalassemia . 
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The pattern of GH secretion and IGF-1 were analysed and compared in two groups of children; a 
group of children with thalassemia and a group of normal children. 
Children with thalassemia were randomly selected from children with thalassemia admitted to 
University of Science Malaysia Hospital for blood transfusion from October 1993 to October 
1995. All the children require regular blood transfusion to maintain their haemoglobin between 
1 0-12 gmJL and none of the children were on chelation therapy with desferroxarnine. 
Splenectomy was already performed in 10 thalassemic children at a mean age of 6.8 years. 
Criteria for the diagnosis of thalassemia were as previously reported [13). None of the patients 
gave a family history of malnutrition, diabetes mellitus, dwarfism or other endocrine diseases. 
Children in the normal grop~ were selected from healthy children of staff members and patients 
- ~ 
-
who were well. All the children studied were between 6-12 years old. 
The heights of all children were measured to the nearest .0.1 ern ~smg a wall. mounted 
stadiorneter. Bone age was detennined from a radiograph of the left wrist using the Greulich and 
Pyle atlas. The severity of iron overload was estimated by measuring the serum ferritin. 
6 
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arowth Hormone Stimulation Tests 
i) Exercise Test 
On the day of admission an exercise-induced GH stimulation test was performed by asking all 
children to climb stairs vigorously for a duration of 15-20 minutes. Blood was collected before 
the exercise, immediately postexercise and 30 minutes after rest. The exercise test was not done 
in two children. One child died before the exercise test could be done and another child refused 
to perform the test. 
ii) Glucagon Stimulation Test 
Studies were done in the morning at 0830 hr in fasting, recumbent subjects. A 23-gauge cannula 
was inserted into a peripheral vein in the forearm or cubital fossa. at least 30 minutes before the 
.:..'ft. 
study. Patency was mainrttiJ',red with heparin in saline (1 in 1000 dilution). After collection of one 
baseline sample, all subjects received a slow bolus of intravenous glucagon in a dosage of 0.15 
mglkg. Blood was collected from the intravenous cannula 30, 60, 90 and 120 minutes after 
intravenous glucagon for the estimation of serum GH and random blood sugar. Blood collected 
before glucagon administration was also estimated for serum insulin growth factor-! (IGF-1 ), 
thyroxin (T4) and thyroid stimulating hormone (TSH). During the whole procedure the pulse 
and blood pressure were mo.nitored. 
All blood specimen for growth hormone and IGF-1 estimation were collected in a glass tube. 
After clotting at 4°C the blood was centrifuged and serum stored at -20 °C until the 
radioimmunoassay was done. 
I 
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r-Esumation of serum growth hormone and IGF-1 
Se~m GH was estimated by radioimmunoassay using a double antibody human growth honnone 
kit from Diagnostic Products Corporation and serum IGF-1 was estimated radioimmunoassay 
using a double antibody kit from Incstar. The intra and inter assay coefficientS of variation were 
5% and 7% respectively. 
Blood glucose was measured with glucose PAP using a glucose oxidase method. The serum 
,. 
femtiz:t was estimated using a "two-site" imrnunoradiometric assay. Serum thyroid stimulating 
hormone and thyroxin was also determined by radiometric assay. 
Informed consent was obtained from the parents of these children. Approval for the study was 
obtained from the ethical committee of the university . 
.. 
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A total of 32 children was studied. There were 22 children in the thalassemia group with 4 ~-
thalassemia major and 18 HbE/~-thalassemia patients. Ten normal children were studied as 
controls. In the control group there were 5 normal volunteers, 1 child with a closed ventricular 
defect, 1 child with typhoid one month after recovery, 1 child with acute gastroenteritis one 
month after recovery and 1 child who was admitted for a mild hornet sting. 
The ·clinical characteristics of all the children were as shown in Table 1. The mean 
chronological age of thalassemia patients (8.6 years) was not significantly (p = 0.22) different 
from the mean chronological age of normal children (9.5 years). The mean bone age in 
thalassemic patients (7.3 years) was also not significantly (p = 0.24) different from the mean 
bone age of normal children (8.5 years) .. The mean difference between chronological and bone 
age in thalassemia patients (1.2 years) was not significantly (p = 0.77) different from that in 
normal children (0.9 years.f; There were no significantly differences in the sex between the 
-
thalassemia and normal group (p = 0.45). All the children studied were Malays except for 3 
Chinese and 1 Thai in the thalassemia group. 
Table 2 shows the Z-scores for height of thalassemia and normal children. The mean Z-score of 
normal children (-1.1) was significantly (p = 0.04) less than that of thalassemia children (0.9). 
This suggests that children in the thalassemia group were not short as compared to children in 
the normal group. 
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levels (Table 3) as expected was significantly higfier (p = <0.0001) in 
thalassemic children than the normal children as all the thalassemia children his received regular 
blood transfusions. Table 4 shows the serum T4 and serum TSH in these children. The mean 
seruni T4 level in thalassemia group (96.9 umol!L) was not significantly (p = 0.42) different 
from that in the normal group (91.3 umol!L). The serum TSH however was significantly (p = 
0.009) higher in thalassemia children (2.9 iu/L) as compared to the normal group (1.7 iu!L). The 
range of serum TSH in patients with thalassemia however was only 0.9 - 6.2 iu/L. 
, .. 
Results of GH release after exercise and glucagon stimulation were as shown in Table 5 and 
Table 6. There was no significant difference (p = 0.37) in the mean peak GH levels after 
exercise in thalassemic children (4.2 ug/L) and in normal children (3.6 ug/L). There was also no 
significant difference (p = 0.5) in the peak serum GH levels following glucagon provocation in 
thalassemia (3.8 ug!L) and normal children (4.8 ug!L). The mean serum IGF-1 levels (Table 7) 
.• 
- . 
however was significan1~ higher (p = 0.001) in the normal (25.5 ng/L) than the thalassemia 
children (12.3 ng!L). 
There was no correlation between chronological age and serum ferritin in thalassemia children (r 
=- 0.04). There was only a weak negative correlation between serum ferritin and peak growth 
hormone levels after exercise (r = - 0.30) and glucagon stimulation (r = -0.29) . There was also 
no correlation between serum ferritin and serum IGF-1 levels (r = 0.01 ). 
: 
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The present study was perfom1ed on a homogenous group of prepubertal patients receiving 
regular transfusion but no chelation therapy with desferroxamine. Unlike most previous studies 
which were done in patients with P-thalass.ernia major, 18 (81.8%) of our patients have HbE/P-
thalassemia and only 4 (18.2%) were children with P-thalassemia major. The only difference 
between the thalassemia group and normal children was a significantly lower serum level of 
IGF-1 in children with thalassemia. There was no difference in the secretion of GH between the 
two groups either following exercise or glucagon provocation. 
The poor secretion of growth hormone even in children in the normal group could not be easily 
explained. Although there were only 5 normal volunteers the medical conditions in the other 
children in the normal group is unlikely to have affected the pattern of growth hormone 
secretion. The exercise test was not objective as children were asked to run up and down stairs 
.• 
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for 15-20 minutes. Diffictmy in getting children to cooperate in the exercise test may result in a 
low level of stress achieved following exercise. The degree of stress following exercise also 
could not be assessed objectively. 
The dosage of glucagon used in this study (0.15 mg/kg) was higher than the dosage 
recommended [14]. Previous studies have shown that doses glucagon as low as 15 ug/kg is 
sufficient to stimulate growth hormone secretion in children [15]. Unlike the insulin tolerance 
test where a clearly described standardised stimulus is applied and a quantifiable hypoglycaemia 
sti~ulus is produced, the glucagon test do not have a measurable standard of stress. However, 
11 
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children in this study did have side-effects of glucagon administration such as vomiting 
and headaches suggesting that the stress from glucagon was sufficient. 
The thyroid status in these children should not have blunted the growth hormone response as the 
serum thyroxin was normal. Even though the thyroid stimulating hormone (TSH) was 
significantly higher in patients with thalassemia the level the highest level of TSH was only 6.2 
units/L, which is not pathologically raised. 
Prevlous studies of GH response to provocative tests in children with thalassemia have shown 
conflicting results. Although growth retardation is common in · patients with thalassemia, 
provocative testing of growth hormone response was normal in many studies [5,6,9,10]. On the 
other hand there are other studies showing impaired GH response in children with thalassemia 
[15,16,17]. 
A major difference betwee~ children in this and other studies that show a normal GH response is 
- A. 
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-the younger age of the children compared to those studies which reported abnormal GH 
responses. It is conceivable that the encountered difference reflects chronic effects of tissue iron 
deposition that has not occurred in our patients. The height of children in the thalassemic group 
in this study was significantly lower than that of children in the normal group suggesting that 
children with thalassemia were not short. The bone age was also not significantly more delayed 
as compared to the normal group. In older children where chronic tissue iron d~position has 
cause more damage the GH release following stimulation has been shown to be abnormal 
leading to short stature [ 15, 16]. 
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thalassemia there was an inverse relationship between serum ferritin and peal(. growth hormone 
concentration [15]. Although the duration of iron overload is predominantly related to age, there 
is no clear relation between age and growth hormone deficiency in our patients with thalassemia. 
An abnormal GH response was not only related to iron overload, as thalassemic children who 
had never received blood transfusion also demonstrated an abnormal HG response suggesting 
that chronic anaemia and chronic hypoxia per se may cause abnormal GH secretion [17]. 
Normal GH response to provocative stimuU in the presence of short stature in many studies has 
lead others to investigate IGF-1 levels, and neurosecretary function in thalassemic patients. 
Shehadeh et al showed that in a group of thalassemic patients with growth retardation, GH 
responses to provocation test was normal but spontaneous GH secretion over a period of 24 
hours was abnormal suggesting the presence GH neurosecretary dysfunction . [ 10]. Reduced 
serum levels of IGF-1 in the presence of normal GH response in thalassemic children has also 
.. 
been shown in many other iitldies [1,2,3,4,5,12]. 
The aetiology of low serum somatomedins of IGF-1 is less clear. Among the possible causes 
postulated are 1) the presence of inhibitors of somatomedin of IGF-1 in thalas.semic sera 2) an 
abnormal GH-receptor interaction resulting from an abnormal GH molecule, an abnormal GH 
receptor or perhaps, the presence of a nonreceptor GH-binding protein in thalassemic sera, 3) 
impaired somatomedin or IGF-1 synthesis (or release) due to hepatic iron deposition or tissue 
hypoxia, and 4) a disturbance of carrier protein synthesis or availability. 
13 
et al [11] showed that low levels of nonsuppressible insulin-like activity m 
thalassemia major is not due to the presence of inhibitors or to impairment o(GH binding to its 
receptor, either as a result of iron or ferritin effects or as a result of an abnormal GH molecule. 
They suggest that the most likely, but as yet untested causes are the presence of either an 
abnormal GH' receptor or a metabolic defect in the liver cells that decreases their ability to 
synthesise and/or secrete nonsuppressible insulin like activity and/or its binding proteins. A 
possible defect at the receptor or post-receptor level was suggested when Werther et al [18] 
showed no rise of serum nonsuppressible insulin-like activity following adrrunistration of 
exogenous growth hormone in children with thalassemia No relationship however was found 
between the severity of growth retardation and the human GH binding to liver membranes in 
liver tissue specimens, suggesting that a defect in GH-receptor interaction in liver membranes is 
not the main cause of growth failure [19]. It is possible that the defect responsible for reduced 
IGF-1 generation is in the postreceptor region . 
.. 
-. ~ ~ 
The major site of somatomedin generation is the liver [20,21] It is known that patients with 
thalassemia major accumulate large quantities of iron (as ferritin ) in their liver, as well as other 
organs, secondary to the repeated blood transfusions and increased intestinal absorption [22] Iron 
is known·to interfere with membrane and other cellular functions [23] and may therefore impair 
receptor or post receptor processes. Besides hepatic iron deposition due to repeated transfusions, 
tissue hypoxia due to chronic anaemia, could also interfere with IGF-1 production by the liver in 
these children. 
14 
In summary, this examination of a group of prepubertal thalassemic patients most of whom are 
HbE/~-thalassemia has shown that GH secretion, as evaluated by the responses to exercise and 
glucagon stimulation, is not impaired, while the generation of serum IGF-1 is reduced. 
Comparison of these data with those of other published reports indicate that impairment of GH 
secretion may occur later in the course of the disease. Liver damage secondary to excessive iron 
deposi~on causing a reduction in IGF-1 production precedes the impairment of GH release and 
may also lead to short stature. The achievement of relatively constant haemoglobin levels and 
reduction of tissue iron stores with long term iron chelation therapy is needed to prevent these 
endocrine abnormalities. 
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USTRATIONS 
TABLEl 
Clinical data of 22 thalassemic and 10 normal children 
... Thalassemia Control 
Group Group 
n=22 n= 10 
Chronological Age (Years) Mean 8.6* . 9.5 
, ..
Median 8.0 9.7 
Range 5.6- 13 5.8- 12.4 
Bone Age (Years) . Mean 7.3** 8.5 
Median 7.4 8.7 
Range 3.0- I 1.5 6.0- 10.0 
Difference betweefi,t Mean 1.2 1.0 
chronological and oone age 
(Years) 
Median 1.3 I. I 
Range -0.1 to 3.3 -0.2 to 1.9 
Sex Male*** 9 6 
Female 13 4 
I Malay 18 10 I Race 
I 
Chinese 3 0 
Thai 1 0 
t • 
*p=0.22 **p= 0.24 *** p= 0.45 
i 
I 
I 
'20 
, .. 
·Table2 
Z-Scores of Thalassemia and Control Group 
2-Scores 
Mean 
Median 
StdDev 
Ran e 
p=0.04 
Table·3 
Thalassemia Group 
n=22 
- 0.9 
-2.3 
4.6 
-4.9 to 10 
Control Group 
n= 10 
- 1.1 
- 1.3 
1.0 
-2.4 to 0.8 
Serum Ferritin Levels in Thalassemia and Control Group 
-t;- Thalassemia Group Control Group ... 
Serum Ferritin (ug/L) n=22 n= 10 
Mean 2256 58 
Median 1954 52 
StdDev 1684 25 
Range 520-7000 28- 107 
p= < 0.0001 
21 
/ 
. ;, 
t. 
, .. 
Table4 
Serum thyroxin (T4) and thyroid stimulating hormone (fSH) 
in thalassemia group and control group 
... 
SerumT4 
Levels 
(umol/L) 
SerumTSH 
Level 
(iu/L) 
TableS 
.. 
- ... -~ ,.. 
-
Mean 
Median 
StdDev 
Range 
Mean 
Median 
StdDev 
Range 
* p= 0.43 
**P=0.009 
Thalassemia Control Gorup 
Group n= 10 
n=22 
96.9* 91.3. 
100 87.5 
16.8 17.7 
68- 136 67- 118 
2.9** 1.7 
2.7 1.8 
1.3 0.7 
0.9-6.2 0.7-2.7 
Serum Growth Hormone Levels After Exercise Test 
Serum Growth Thalassemia Group Control Group 
Hormone (ug/L) n=20 n= 10 
Mean 4.2 3.6 
Median 3.3 2.3 
StdDev 3.6 3.5 
Range 0.9- 14.5 0.9- 10.4 
p= 0.37 
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Table6 
Peak Serum Growth Hormone Levels After 
Glucagon Stimulation Test 
Serum Growth Thalassemia Group Control Group 
Hormone (ug/L) n=22 n= 10 
. 
Mean 3.8 4.8 
Median 3.0 3.5 
StdDev 2.6 4.0 
Range 0.9-10.4 0.9- 13.0 
p=0.5 
Table 7 
Serum IGF-1 in children with Thalassemia and Controls 
Serum IGF-1 (ng/L) Thalassemia Control Group 
Group n= 10 
n=22 
Mean 12.3 25.5 
Median 11.3 23.7 
StdDev 6.6 11.4 
Range 4.0-32.6 10.4-49.8 
p=0.001 
